Michael Braun-Boghos

Send us Fan Mail

Embark on a journey through the dynamic world of pharmacovigilance with Michael Braun-Boghos, the seasoned Senior Director of Safety Strategy at Oracle. In our first  episode of the season, Michael unpacks his three-decade odyssey from the analog days of adverse event forms to the digital frontier of pharmacovigilance. As we traverse his career landscape, the evolution from paper trails to strategic IT roles unfolds, highlighting pivotal shifts and the integrative prowess of systems like Argus. Michael's anecdotes from the merge that birthed Astellas to the strategic tides at Relsys before its acquisition by Oracle offer a rare glimpse into the industry's transformation.

This episode is a deep dive into the sea of innovation that is healthtech, where the currents of patient safety and regulatory compliance meet. Michael defends the gradual innovation ethos that Argus embodies within the high-stakes realm of pharmacovigilance, underscoring its necessity amidst an industry where risk is a constant companion. Our discussion also sails into the partnership between software providers and health authorities, the burgeoning concept of 'touchless cases', and the cautious yet crucial adoption of AI. Prepare to be enlightened by our collaborative narrative that stresses the importance of evolving procedures to harness technology's full potential without sacrificing safety.

Looking towards the horizon, we cast a net over the transformative impact of automation and AI on pharmacovigilance. Michael paints a future where Argus and similar tools streamline processes, and the integration of real-world data is set to revolutionize drug safety monitoring. We tackle the utilization of diverse data sets, from electronic health records to the untapped vistas of social media, and discuss how this influx of information is carving a path for precision in pharmacovigilance. Michael's personal reflections on the intrinsic rewards of contributing to global health safety, coupled with an exploration of the precision needed for enhanced patient outcomes, brings our episode to a close, leaving listeners with a profound understanding of the commitment to innovation and patient safety that defines the field's future.